Categories: Research

Voigt pioneers field of synthetic biology

Christopher A. Voigt, PhD, UCSF School of Pharmacy scientist, and colleagues are engineering bacteria to target tumors and create images.

Ortiz de Montellano, Voigt, and Wells recognized for their science

Three UCSF School of Pharmacy scientists, Paul R. Ortiz de Montellano, PhD; Christopher A. Voigt, PhD; and James A.

Memory-making molecules now better understood

Through better understanding of where and how the brain gets, or "traffics," fresh supplies of particular receptors needed to carry chemical signals between nerve cells, researchers hope to better understand how we learn, remember, and possibly forget.

UCSF ranks #1 in chemical research and development funding

For the 2nd consecutive year, UCSF topped all United States universities and colleges in both total and federally financed spending for chemistry research and development. These results reflect data for 2003 from the National Science Foundation. These are the most recent statistics available as of...

Bacteria engineered to produce images

By genetically engineering microbes to act like biological camera film, UCSF School of Pharmacy assistant professor Christopher A. Voigt, PhD and doctoral students show the potential of the new field of synthetic biology to create useful tools for medicine and technology.

Systems biology center connects UC and Peking University

A research collaboration between the University of California (UC) and Peking University will integrate the biological data acquisition strengths of the former with the physical and theoretical strengths of the latter, a move which scientists anticipate will ultimately lead to more effective, safer...

Langridge named innovator of our time

Robert Langridge, PhD, professor emeritus of the School of Pharmacy, University of California, San Francisco, is highlighted as one of 35 innovators of our time by the editors of Smithsonian Magazine in its November 5, 2005 issue.

Physician-focused strategy to cut drug costs failing

Attempts have failed by Health Management Organizations (HMOs) to cut drug costs by putting physicians at financial risk if their prescription costs exceed their medical group's drug budget.

Industry data should be shared

The same level of legal scrutiny that applies to research funded by the US government should apply to research funded by industry, according to UCSF School of Pharmacy faculty member Lisa Bero, PhD, and co-authors of a study that appeared July

Giacomini receives Dawson Award

Kathy M.

Pages